Almost 60 years have passed since the initial discovery by Hubel and Wiesel that changes
in neuronal activity can elicit developmental rewiring of the central nervous system (CNS) …

The potential therapeutic use of some Cannabis sativa plant compounds has been attracting
great interest, especially for managing neuropsychiatric disorders due to the relative lack of …

Schizophrenia (SCZ) is a devastating mental disorder with poorly defined underlying
molecular mechanisms. The gut microbiome can modulate brain function and behaviors …

Schizophrenia is a complex neuropsychiatric syndrome with a heterogeneous genetic,
neurobiological, and phenotypic profile. Currently, no objective biological measures—that is …

Accumulating evidence suggests that gut microbiota plays a role in the pathogenesis of
schizophrenia via the microbiota–gut–brain axis. This study sought to investigate whether …

The stagnation in drug development for schizophrenia highlights the need for better
translation between basic and clinical research. Understanding the neurobiology of …

Although the precise pathogenesis of schizophrenia is unknown, genetic, biomarker and
imaging studies suggest involvement of the immune system. In this study, we performed a …

Antipsychotic drugs are the mainstay in the treatment of schizophrenia. However, one-third
of patients do not show adequate improvement in positive symptoms with non-clozapine …

There is a growing understanding that pathological genetic variation and environmental
insults during sensitive periods in brain development have long-term consequences on …

Genomic structural variants have long been implicated in phenotypic diversity and human
disease, but dissecting the mechanisms by which they exert their functional impact has …